404 Shares in IDEXX Laboratories, Inc. $IDXX Purchased by HTG Investment Advisors Inc.

Key Points

• HTG Investment Advisors Inc. acquired 404 shares of IDEXX Laboratories, Inc. for approximately $217,000 in the second quarter, marking their first stake in the company.
• IDEXX Laboratories reported $3.63 EPS in its latest quarterly earnings, exceeding analyst estimates and showing a 10.6% increase in revenue year-over-year.
• A recent analysis by brokerages resulted in new price targets for IDEXX Laboratories, with Piper Sandler raising its target to $700.00 and BTIG Research increasing it to $785.00, indicating strong market confidence.

HTG Investment Advisors Inc. purchased a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 404 shares of the company's stock, valued at approximately $217,000.

Several other hedge funds have also recently modified their holdings of IDXX. Mutual of America Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 79.6% in the first quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company's stock worth $8,160,000 after buying an additional 8,609 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of IDEXX Laboratories by 3,766.7% in the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock worth $49,000 after buying an additional 113 shares in the last quarter. Plato Investment Management Ltd raised its position in IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company's stock valued at $1,310,000 after purchasing an additional 835 shares during the period. Sagespring Wealth Partners LLC bought a new stake in IDEXX Laboratories in the first quarter worth $229,000. Finally, Genesis Wealth Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $215,000. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $627.78 on Tuesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a 50 day moving average price of $635.75 and a 200 day moving average price of $537.82. The stock has a market capitalization of $50.22 billion, a P/E ratio of 52.27, a PEG ratio of 4.09 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the firm posted $2.44 earnings per share. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In related news, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This trade represents a 46.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares of the company's stock, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,057 shares of company stock worth $34,293,468. Insiders own 0.98% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IDXX. Jefferies Financial Group initiated coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Weiss Ratings reiterated a "buy (b-)" rating on shares of IDEXX Laboratories in a research note on Saturday, September 27th. BTIG Research increased their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research note on Monday, August 4th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.